Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer.
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be sufficient because of tumor heterogeneity. A focus on examining global biomarker expression or activity, particularly in microscopic residual chemotherapy-resistant disease, is needed for the appropriate se...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
John Wiley and Sons Inc.
2015
|
| _version_ | 1797090657487028224 |
|---|---|
| author | Liu, S Zheng, Y Volpi, D El-Kasti, M Klotz, D Tullis, I Henricks, A Campo, L Myers, K Laios, A Thomas, P Ng, T Dhar, S Becker, C Vojnovic, B Ahmed, A |
| author_facet | Liu, S Zheng, Y Volpi, D El-Kasti, M Klotz, D Tullis, I Henricks, A Campo, L Myers, K Laios, A Thomas, P Ng, T Dhar, S Becker, C Vojnovic, B Ahmed, A |
| author_sort | Liu, S |
| collection | OXFORD |
| description | BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be sufficient because of tumor heterogeneity. A focus on examining global biomarker expression or activity, particularly in microscopic residual chemotherapy-resistant disease, is needed for the appropriate selection of targeted therapies. This study was aimed at establishing a technique for the assessment of biomarkers of ovarian cancer peritoneal spread. METHODS: An in-house developed fluorescent imaging device was used to detect the expression of the c-Met oncogene in ovarian cancer. A modified cyanine 5-tagged peptide, GE137, with a high in vitro affinity for the human c-Met protein, was tested in a panel of ovarian cancer cell lines. Finally, the feasibility of detecting submillimeter ovarian cancer cell peritoneal metastases in vivo was tested through the intravenous injection of GE137 into mice with tumor xenografts. RESULTS: Using optical imaging it was possible to detect c-Met expression in submillimeter peritoneal metastases that were freshly excised from a human high-grade serous ovarian cancer. GE137 selectively bound to the c-Met tyrosine kinase without activating survival signaling pathways (AKT or extracellular signal-regulated kinase phosphorylation) downstream of c-Met. GE137 specifically accumulated in SKOv3 ovarian cancer cells expressing c-Met via clathrin-mediated endocytosis and emitted a fluorescent signal that lasted for at least 8 hours in tumor xenografts in vivo with a sustained high signal-to-noise ratio. CONCLUSIONS: Our results suggest that intraoperative optical imaging could provide a new paradigm for selecting cancer patients for appropriate targeted therapies, particularly after initial chemotherapy. Cancer 2015;121:202-13. © 2014 American Cancer Society. |
| first_indexed | 2024-03-07T03:21:49Z |
| format | Journal article |
| id | oxford-uuid:b7affb44-1dc9-46c4-afa7-f31e3cb7fa6f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:21:49Z |
| publishDate | 2015 |
| publisher | John Wiley and Sons Inc. |
| record_format | dspace |
| spelling | oxford-uuid:b7affb44-1dc9-46c4-afa7-f31e3cb7fa6f2022-03-27T04:50:34ZToward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b7affb44-1dc9-46c4-afa7-f31e3cb7fa6fEnglishSymplectic Elements at OxfordJohn Wiley and Sons Inc.2015Liu, SZheng, YVolpi, DEl-Kasti, MKlotz, DTullis, IHenricks, ACampo, LMyers, KLaios, AThomas, PNg, TDhar, SBecker, CVojnovic, BAhmed, ABACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be sufficient because of tumor heterogeneity. A focus on examining global biomarker expression or activity, particularly in microscopic residual chemotherapy-resistant disease, is needed for the appropriate selection of targeted therapies. This study was aimed at establishing a technique for the assessment of biomarkers of ovarian cancer peritoneal spread. METHODS: An in-house developed fluorescent imaging device was used to detect the expression of the c-Met oncogene in ovarian cancer. A modified cyanine 5-tagged peptide, GE137, with a high in vitro affinity for the human c-Met protein, was tested in a panel of ovarian cancer cell lines. Finally, the feasibility of detecting submillimeter ovarian cancer cell peritoneal metastases in vivo was tested through the intravenous injection of GE137 into mice with tumor xenografts. RESULTS: Using optical imaging it was possible to detect c-Met expression in submillimeter peritoneal metastases that were freshly excised from a human high-grade serous ovarian cancer. GE137 selectively bound to the c-Met tyrosine kinase without activating survival signaling pathways (AKT or extracellular signal-regulated kinase phosphorylation) downstream of c-Met. GE137 specifically accumulated in SKOv3 ovarian cancer cells expressing c-Met via clathrin-mediated endocytosis and emitted a fluorescent signal that lasted for at least 8 hours in tumor xenografts in vivo with a sustained high signal-to-noise ratio. CONCLUSIONS: Our results suggest that intraoperative optical imaging could provide a new paradigm for selecting cancer patients for appropriate targeted therapies, particularly after initial chemotherapy. Cancer 2015;121:202-13. © 2014 American Cancer Society. |
| spellingShingle | Liu, S Zheng, Y Volpi, D El-Kasti, M Klotz, D Tullis, I Henricks, A Campo, L Myers, K Laios, A Thomas, P Ng, T Dhar, S Becker, C Vojnovic, B Ahmed, A Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title | Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title_full | Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title_fullStr | Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title_full_unstemmed | Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title_short | Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. |
| title_sort | toward operative in vivo fluorescence imaging of the c met proto oncogene for personalization of therapy in ovarian cancer |
| work_keys_str_mv | AT lius towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT zhengy towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT volpid towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT elkastim towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT klotzd towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT tullisi towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT henricksa towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT campol towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT myersk towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT laiosa towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT thomasp towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT ngt towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT dhars towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT beckerc towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT vojnovicb towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer AT ahmeda towardoperativeinvivofluorescenceimagingofthecmetprotooncogeneforpersonalizationoftherapyinovariancancer |